# Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

> **NCT06087653** · PHASE1,PHASE2 · RECRUITING · sponsor: **Starton Therapeutics, Inc** · enrollment: 24 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Lenalidomide 25 MG Oral Capsule

## Key facts

- **NCT ID:** NCT06087653
- **Lead sponsor:** Starton Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087653, "Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06087653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*